- Home
- PIM vs CHRS Comparison
PIM vs CHRS Comparison
Compare PIM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- CHRS
- Stock Information
- Founded
- PIM 1988
- CHRS 2010
- Country
- PIM United States
- CHRS United States
- Employees
- PIM N/A
- CHRS N/A
- Industry
- PIM Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PIM Finance
- CHRS Health Care
- Exchange
- PIM Nasdaq
- CHRS Nasdaq
- Market Cap
- PIM 162.4M
- CHRS 156.0M
- IPO Year
- PIM N/A
- CHRS 2014
- Fundamental
- Price
- PIM $3.37
- CHRS $1.29
- Analyst Decision
- PIM
- CHRS Buy
- Analyst Count
- PIM 0
- CHRS 6
- Target Price
- PIM N/A
- CHRS $7.10
- AVG Volume (30 Days)
- PIM 57.5K
- CHRS 1.6M
- Earning Date
- PIM 01-01-0001
- CHRS 11-04-2024
- Dividend Yield
- PIM 8.28%
- CHRS N/A
- EPS Growth
- PIM N/A
- CHRS N/A
- EPS
- PIM 0.05
- CHRS N/A
- Revenue
- PIM N/A
- CHRS $308,134,000.00
- Revenue This Year
- PIM N/A
- CHRS $6.15
- Revenue Next Year
- PIM N/A
- CHRS $15.04
- P/E Ratio
- PIM $63.80
- CHRS N/A
- Revenue Growth
- PIM N/A
- CHRS 69.37
- 52 Week Low
- PIM $2.90
- CHRS $1.20
- 52 Week High
- PIM $3.28
- CHRS $4.97
- Technical
- Relative Strength Index (RSI)
- PIM 57.02
- CHRS 46.26
- Support Level
- PIM $3.33
- CHRS $1.26
- Resistance Level
- PIM $3.42
- CHRS $1.37
- Average True Range (ATR)
- PIM 0.04
- CHRS 0.09
- MACD
- PIM -0.00
- CHRS 0.00
- Stochastic Oscillator
- PIM 56.67
- CHRS 35.19
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.